Illumina Q3 2026 Revenue Rises 4.2% to $1.13 Billion
Illumina posted $1.13 billion in third-quarter revenue, a 4.2% year-over-year gain, the genomics company reported Wednesday.
Illumina, Inc. reported third-quarter fiscal 2026 revenue of $1.13 billion, the San Diego-based genomics technology company announced Thursday, marking a 4.2% increase compared with the same period a year earlier.
The result continues a modest growth trajectory for the Nasdaq-listed firm, which manufactures DNA sequencing instruments and consumables used widely in research, clinical diagnostics, and pharmaceutical development. A year-over-year revenue gain of this magnitude signals stabilizing demand across its customer base following a period of strategic restructuring at the company.
Read more MGIC Investment Declares $0.17 Quarterly Cash Dividend →
Illumina has been working to sharpen its focus on core sequencing operations after divesting non-core assets in prior fiscal periods. Analysts have closely tracked whether the company's consumables business — which tends to reflect real-world utilization of its installed instrument base — is keeping pace with hardware placements, a key metric for long-term revenue sustainability.
The quarterly report offers investors an early look at sequencing market conditions heading into the final stretch of fiscal 2026. Broader trends in genomics spending, including funding pressures at academic research institutions and expanding adoption in clinical settings, continue to shape Illumina's near-term revenue outlook.
Continue reading at Earnings.
